JelikaLite

JelikaLite

医疗设备制造业

New York,NY 724 位关注者

Developing an intelligent medical device for children on the autism spectrum

关于我们

Autism is a serious developmental disease that lasts a lifetime. The rates of autism continue to rise, the cause of the disease remains unknown and there is no cure. We believe that children on the autism spectrum can lead fulfilling and productive lives. That is why JelikaLite is developing Cognilum, an integrative solution with focus on pediatric neurological health using non-invasive novel therapies. Cognilum will enable children to integrate into society, parents to receive a home-based personalized cost-effective treatment while having a better quality of life, therapists to track progress and efficacy of existing interventions, and both payors and government to spend less money on special education and lifelong residential care. Cognilum may provide benefits that may be difficult to measure with money alone, yet society will bear the ultimate expenses if nothing continues to be done about the millions of children with autism and other neurological disorders who are unable to integrate into society.

网站
https://jelikalite.com
所属行业
医疗设备制造业
规模
2-10 人
总部
New York,NY
类型
私人持股
创立
2019
领域
Medical Devices、Health、Technology、Autism和Artificial Intelligence

地点

  • 主要

    30 Wall Street

    8th Floor

    US,NY,New York,10005

    获取路线

JelikaLite员工

动态

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    JelikaLite is hiring! Revolutionizing Autism Treatment Through Innovative Technology. We're seeking a talented Software Engineer to join our mission-driven startup developing groundbreaking solutions for children with autism. As a key member of our small, dedicated team, you'll design and build our proprietary Cognilum AI/ML Platform, personalizing treatment through data-driven insights. What You'll Do: - Architect and develop a HIPAA-compliant, multi-user platform for treatment personalization - Create robust data models for patient profiles, questionnaires, and treatment sessions - Build responsive web and mobile applications with cutting-edge technologies Implement rigorous quality assurance processes to ensure platform reliability You Should Have: - Bachelor's degree in Computer Science or related field - Full-stack development expertise (React, Python, SQL, cloud platforms), Mobile app development experience (iOS and Android) - Strong understanding of cybersecurity best practices - Passion for creating technology that makes a meaningful difference Join us in transforming the future of autism care through innovative software solutions. If you're ready for a challenging and rewarding role with significant impact, we want to hear from you!

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    We are thrilled to announce that?JelikaLite?has been awarded a 2-year, $959,000 National Science Foundation (NSF) grant to?develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children.??The project's objectives are to finalize the current clinical prototype into a manufacturing-ready product and implement a platform for personalizing transcranial photobiomodulation (tPBM) treatment based on individual sensor -derived patient characteristics. Results could?enrich scientific knowledge through personalization, monitoring, and data aggregation of neurological measures for further elucidating the mechanisms of autism and enhancing the efficacy of other therapies. Read more?here https://lnkd.in/e23Yj74y. ?This achievement not only marks a significant milestone for JelikaLite but also serves as a strong endorsement of our pioneering approach in the medical field. The grant will enable us to accelerate our development, expand our team, and bring this transformative technology closer to the?families who need it. We extend our heartfelt thanks to the NSF, our investors, and all stakeholders for their invaluable support. Your belief in our vision is crucial as we work together to create a brighter future for autistic children and their families. We are eager to continue this journey and are deeply grateful for the ongoing support from our community. Together, we are making a meaningful impact!

    SBIR Phase II: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism

    SBIR Phase II: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism

    nsf.gov

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    I am thrilled to recommend Valdis Ling, who has been an outstanding intern at JelikaLite Corp for the past 4 months. At JelikaLite, a medical device startup focused on technology for children with Autism Spectrum Disorder (ASD), Valdis has shown exceptional dedication and skill from day one. ?? Key Contributions: Cash Flow Model Enhancement: Valdis utilized his expertise in statistical modeling and Excel coding to significantly improve our Cash Flow model. He meticulously researched, validated, and updated assumptions, redesigned layouts, and revised formulas. His technical prowess, combined with flexibility, initiative, and independence, has been remarkable. Investor Research Project: Valdis has also taken on a crucial research project to identify potential investors using Pitch Book and Crunchbase platforms. The insights he has provided are invaluable for our fundraising goals. Valdis’s enthusiasm for learning and passion for problem-solving truly set him apart. He approaches each task as an opportunity to grow and make a meaningful impact, especially in improving the lives of children with autism. Based on his contributions to JelikaLite and his evident potential, I am confident that Valdis will excel in any academic and professional setting. I wholeheartedly recommend Valdis and am convinced that he will be a valuable addition to any project.

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    Thank you LSI for giving us an opportunity to present and to meet amazing people!

    查看LSI的公司主页,图片

    21,531 位关注者

    In a galaxy not so far away, the LSI Alumni are reaching for the stars with another week of incredible milestones ???? This week the #LSIAlumni raised $28M, received FDA Breakthrough Device Designation, surpassed 1,000 successful procedures, and much more on the road to #LSIEurope24. Your 60-second news recap: 4C Medical Technologies, Inc.Saravana Kumar → Granted FDA Breakthrough Device Designation for its AltaValve transcatheter mitral valve replacement (TMVR) device for two indications. AccelusKevin McGann → Announced the appointment of Chris McKee as Vice President of Regulatory & Quality. AdialanteEfraín Torres, PhD → Awarded a grant from The University of Minnesota Office of Discovery & Translation. DistalmotionGreg Roche? → Surpassed 1,000 successful procedures with its surgical robot, Dexter. Hyperfine, Inc.Maria Sainz → Entered into agreements with three distributors to support commercial expansion plans of its Swoop system into European markets. → Additionally, Hyperfine announced the expansion of its management team, with Enrico Barini joining as international business development director. JelikaLiteLuis De Taboada → Published clinical trial results demonstrating their Cognilum? device, significantly improves symptoms of autism spectrum disorder (ASD) in children aged 2 to 6 years. May HealthAnne Morrissey → Raised a $25M Series B funding round co-led by Bpifrance and Trill Impact. MEXBRAINThomas Brichart → Announced positive results from the preclinical trials of its oral drug, DECoRP. NovaResp - Respiratory AIHamed Hanafi → Raised a $3M Seed extension round to support clinical testing of its cMAP? positive airway pressure system. Provisio MedicalS. Eric Ryan, M.D., John Blake → Completed the first commercial clinical cases utilizing the Provisio? SLT IVUS? System. ScreenPoint Medical → Announced the appointment of Pieter Kroese as the new CEO. Congratulations to all the LSI Alumni who made major news this week!

  • JelikaLite转发了

    查看Katya Sverdlov, CFA, Esq.的档案,图片

    Co-Founder and CEO, Jelikalite. Principal at Sverdlov Law PLLC. Board Member.

    We are really excited to share this amazing milestone for JelikaLite. A publication in Frontiers in Neurology of our groundbreaking study using Cognilum to improve communication and responsiveness in autistic children. https://lnkd.in/eJ_rx-xs

    查看JelikaLite的公司主页,图片

    724 位关注者

    “Your brain on Light” – light therapy for Autism Spectrum Disorder. ???? ? We’re thrilled to share a significant achievement for JelikaLite. Our groundbreaking study, “Transcranial Photobiomodulation in Children Aged 2–6 Years: A Randomized Sham-Controlled Clinical Trial Assessing Safety, Efficacy, and Impact on Autism Spectrum Disorder Symptoms and Brain Electrophysiology,” has been published in Frontiers in Neurology ??. You can access the full manuscript here: ? This study offers preliminary evidence of the safety and therapeutic potential of transcranial photobiomodulation (light therapy) for children with autism. Specifically, it demonstrates a reduction in core autism spectrum disorder symptoms and modulation of their brain electrophysiology. ???? ? Moreover, our study pioneers the use of EEG as a biomarker to measure treatment efficacy. In an industry where approved biomarkers for autism are currently non-existent, JelikaLite stands as the first company to observe and document the abnormal power of delta waves in its participants and its reduction in the active group only over the course of the trial. Importantly, changes in the power of delta waves correlated with changes in CARS scores, suggesting that a reduction in the power of delta waves in the active group could indicate treatment efficacy.? This opens up new possibilities for personalizing and optimizing treatment strategies. ? This publication is a testament to our team’s years of dedication, perseverance, and innovation in the realms of pediatric neurology and photobiomodulation therapy.? ? Stay connected for more updates as we persist in our mission to push the boundaries of pediatric neurology and enhance the lives of children and families impacted by neurological disorders. Together, we’re making a difference! ??? ? #JelikaLite #MedTech #PediatricNeurology #Photobiomodulation #Research #FrontiersInNeurology #AutismAwareness #Milestone #Innovation

    Frontiers | Transcranial photobiomodulation in children aged 2–6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology

    Frontiers | Transcranial photobiomodulation in children aged 2–6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology

    frontiersin.org

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    “Your brain on Light” – light therapy for Autism Spectrum Disorder. ???? ? We’re thrilled to share a significant achievement for JelikaLite. Our groundbreaking study, “Transcranial Photobiomodulation in Children Aged 2–6 Years: A Randomized Sham-Controlled Clinical Trial Assessing Safety, Efficacy, and Impact on Autism Spectrum Disorder Symptoms and Brain Electrophysiology,” has been published in Frontiers in Neurology ??. You can access the full manuscript here: ? This study offers preliminary evidence of the safety and therapeutic potential of transcranial photobiomodulation (light therapy) for children with autism. Specifically, it demonstrates a reduction in core autism spectrum disorder symptoms and modulation of their brain electrophysiology. ???? ? Moreover, our study pioneers the use of EEG as a biomarker to measure treatment efficacy. In an industry where approved biomarkers for autism are currently non-existent, JelikaLite stands as the first company to observe and document the abnormal power of delta waves in its participants and its reduction in the active group only over the course of the trial. Importantly, changes in the power of delta waves correlated with changes in CARS scores, suggesting that a reduction in the power of delta waves in the active group could indicate treatment efficacy.? This opens up new possibilities for personalizing and optimizing treatment strategies. ? This publication is a testament to our team’s years of dedication, perseverance, and innovation in the realms of pediatric neurology and photobiomodulation therapy.? ? Stay connected for more updates as we persist in our mission to push the boundaries of pediatric neurology and enhance the lives of children and families impacted by neurological disorders. Together, we’re making a difference! ??? ? #JelikaLite #MedTech #PediatricNeurology #Photobiomodulation #Research #FrontiersInNeurology #AutismAwareness #Milestone #Innovation

    Frontiers | Transcranial photobiomodulation in children aged 2–6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology

    Frontiers | Transcranial photobiomodulation in children aged 2–6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology

    frontiersin.org

  • JelikaLite转发了

    查看The BRAIN Foundation的公司主页,图片

    2,197 位关注者

    The BRAIN Foundation is proud to support the first study dedicated to examining the safety and effectiveness of transcranial #photobiomodulation (tPBM) in individuals with #autism and concurrent #epilepsy. Led by Richard Frye MD PhD, the study will assess the reduction of abnormal epileptiform activity and active seizures following tPBM therapy. Additionally, it will contribute to understanding the relationship between brainwave patterns, like the power of wakeful Delta waves, and neurological conditions such as autism, as well as active seizures. Thank you to Dr. Frye for spearheading this important research! This project was funded as part of The BRAIN Foundation 2023 funding round. To find out more about the research we fund and how to apply visit https://lnkd.in/emsPPm8S #translationalresearch #neuroscience #neurology #researchfunding #seizures #fdaapproval #autismspectrumdisorder #biomedicalresearch #biomedicine #science #redlighttherapy

  • 查看JelikaLite的公司主页,图片

    724 位关注者

    If you know a child aged 2 to 8, who has been previously diagnosed with ASD and who lives in the Syracuse NY area - they may be eligible for participation in this study.

    查看The BRAIN Foundation的公司主页,图片

    2,197 位关注者

    AUTISM CLINICAL TRIAL RECRUITING: If your child is 2 to 8 years old and able to attend 30-to-60-minute clinical sessions in the Golisano Center for Special Needs in SUNY Upstate Medical Center in Syracuse, NY, twice a week, for 10 weeks, check out this opportunity to enrol in a clinical trial. The aim of this study is to examine the effectiveness of a novel, non-invasive, light therapy device designed to improve the language and behavior of children with ASD. A therapeutic wearable device combines non-invasive brain stimulation with infrared light. To find out more about this therapy visit: https://lnkd.in/eGXjiWNR To sign up for an early access waitlist for this therapy after commercial launch (anticipated in 2024) visit: https://lnkd.in/gwfPGbuN To check out more clinical trials for autism visit: https://lnkd.in/em2qWHTk #autismspectrumdisorder #autism #clinicaltrial #Neuromodulation #lighttherapy JelikaLite Golisano Autism Center

    • 该图片无替代文字
  • 查看JelikaLite的公司主页,图片

    724 位关注者

    查看Vijay Ravindran的档案,图片

    CEO, Floreo | Amazon and Washington Post alum

    If you missed Floreo’s digital round table moderated by Anastassia Gliadkovskaya of Fierce Healthcare, you are in luck because Anastassia wrote up a great story based on the excellent conversation between Amber Valentino, Solomon J. Parker, Katya Sverdlov, CFA, Esq. and I. So grateful for everyone’s participation to make this happen and special thanks to Anastassia! #vr #wearables #autism #neurodiversity #dtx

    How behavioral health tech can help overcome adoption hurdles among neurodiverse populations

    How behavioral health tech can help overcome adoption hurdles among neurodiverse populations

    fiercehealthcare.com

相似主页

查看职位

融资